UCB's Global Corporate Website

Are you up to the 'Innovation Challenge'?

Posted by
Scott Fleming, UK Communications
03-Feb-2014
At UCB we are constantly looking for innovative ways of  discovering new therapies for severe diseases. Now you can be part of this exciting process of developing the next generation of medicines.

Do you know someone who has a rare phenotype? Maybe they have great healing abilities, exceptional tissue regeneration or are somehow naturally protected from disease.

By better understanding the molecular basis of a rare phenotype, UCB scientists hope to be able to develop new medicines for the treatment of severe diseases, such as rheumatoid arthritis or multiple sclerosis.

UCB has already pioneered a number of exciting new approaches to drug discovery, and has an impressive record for turning discoveries into new medicines for severe diseases but to write the next chapter in our story we are asking for your help.

We have launched the ‘UCB Innovation Challenge’, an online crowd-sourcing project that we hope will create a global super-network of problem solvers and medicine discoverers.
 
Challenge entrants are asked to describe a relevant, interesting and rare human phenotype. The best submission, as determined by an independent Judging Panel, will be eligible for a monetary reward.

Additionally, bonus awards will be paid to entrants who the judges feel have submitted an interesting or relevant entry.

In order to be eligible for an award, submissions must describe phenotypes that can be studied to provide information useful in the development of new disease prevention strategies.

By getting involved, you could help develop new medical treatments, which, ultimately, have the potential to make a real difference to future patients.

Additional information about the UCB Innovation Challenge and entry forms are available online at www.ucbinnovationchallenge.com.

Leave a Comment

By submitting your personal data, you agree with UCB's Data Privacy Policy. Furthermore, for more information on the terms of use of this website please visit our Legal Notice, accessible here.

CAPTCHA

Enter the characters shown in the image.